DK3323814T3 - (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere - Google Patents

(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere Download PDF

Info

Publication number
DK3323814T3
DK3323814T3 DK17195612.1T DK17195612T DK3323814T3 DK 3323814 T3 DK3323814 T3 DK 3323814T3 DK 17195612 T DK17195612 T DK 17195612T DK 3323814 T3 DK3323814 T3 DK 3323814T3
Authority
DK
Denmark
Prior art keywords
dipeptidylpeptidase
oxazepan
carboxamides
phenylethyl
cyano
Prior art date
Application number
DK17195612.1T
Other languages
Danish (da)
English (en)
Inventor
Hans Roland LÖNN
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
Carl-Johan Aurell
John Fritiof Pontén
Kevin James Doyle
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
De Poël Amanda Jane Van
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3323814(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3323814T3 publication Critical patent/DK3323814T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK17195612.1T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere DK3323814T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
EP15701577.7A EP3097086B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
DK3323814T3 true DK3323814T3 (da) 2020-08-03

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17195612.1T DK3323814T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK15701577.7T DK3097086T3 (en) 2014-01-24 2015-01-23 (2S) -N - [(1S) -1-CYAN-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS
DK20173862.2T DK3744714T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15701577.7T DK3097086T3 (en) 2014-01-24 2015-01-23 (2S) -N - [(1S) -1-CYAN-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS
DK20173862.2T DK3744714T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere

Country Status (38)

Country Link
US (19) US9522894B2 (enExample)
EP (4) EP3097086B1 (enExample)
JP (7) JP6469711B2 (enExample)
KR (1) KR102417684B1 (enExample)
CN (2) CN105980367B (enExample)
AP (1) AP2016009322A0 (enExample)
AR (1) AR099177A1 (enExample)
AU (4) AU2015208932C1 (enExample)
BR (1) BR112016016224B1 (enExample)
CA (1) CA2935625C (enExample)
CL (1) CL2016001889A1 (enExample)
CR (1) CR20160327A (enExample)
CY (2) CY1120049T1 (enExample)
DK (3) DK3323814T3 (enExample)
DO (1) DOP2016000175A (enExample)
EA (1) EA032794B1 (enExample)
ES (3) ES2658516T3 (enExample)
FI (1) FI3744714T3 (enExample)
HR (3) HRP20250302T1 (enExample)
HU (3) HUE052421T2 (enExample)
IL (3) IL246614B (enExample)
LT (3) LT3323814T (enExample)
MX (1) MX368840B (enExample)
MY (1) MY194850A (enExample)
NO (1) NO2699580T3 (enExample)
NZ (2) NZ722063A (enExample)
PE (1) PE20161218A1 (enExample)
PH (1) PH12016501439A1 (enExample)
PL (3) PL3744714T3 (enExample)
PT (3) PT3744714T (enExample)
RS (3) RS56919B1 (enExample)
SG (2) SG10201701056QA (enExample)
SI (3) SI3097086T1 (enExample)
SM (3) SMT201800058T1 (enExample)
TW (1) TWI690517B (enExample)
UY (1) UY35963A (enExample)
WO (1) WO2015110826A1 (enExample)
ZA (2) ZA201605856B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
SI3758708T1 (sl) 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
AU2019305565A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
CA3106269A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
JP2022553549A (ja) * 2019-10-23 2022-12-23 チョン クン ダン ファーマシューティカル コーポレーション 慢性閉塞性肺疾患（ｃｏｐｄ）の予防または治療用の組成物
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
WO2022020245A1 (en) * 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
MX2023002371A (es) 2020-08-26 2023-05-19 Haisco Pharmaceuticals Pte Ltd Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo.
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
JP2023551488A (ja) * 2020-12-04 2023-12-08 瑞石生物医薬有限公司 カテプシンｃの小分子阻害剤及びその医薬的使用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN116783189B (zh) * 2021-02-05 2026-01-30 上海复星医药产业发展有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
EP4329767A4 (en) * 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
KR20240099179A (ko) * 2021-10-29 2024-06-28 인스메드 인코포레이티드 만성 비부비동염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
CN118695864A (zh) * 2022-02-16 2024-09-24 英斯梅德股份有限公司 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
IL314852A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Salt and crystal form of dipeptidyl peptidase inhibitor compound
AU2023224769A1 (en) * 2022-02-22 2024-08-29 Haisco Pharmaceuticals Pte. Ltd. Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
US20250179060A1 (en) * 2022-02-22 2025-06-05 Haisco Pharmaceuticals Pte. Ltd. Preparation method of nitrogen-containing heterocyclic compound
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
CN119156384B (zh) * 2022-06-07 2025-12-09 瑞石生物医药有限公司 苯并[c]色满化合物的多晶型及其制备方法和用途
CN119156391A (zh) * 2022-06-07 2024-12-17 瑞石生物医药有限公司 苯并[c]色满化合物的可药用盐、其多晶型及用途
EP4538264A1 (en) 2022-06-13 2025-04-16 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en) 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
CN119948034A (zh) * 2022-10-26 2025-05-06 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en) * 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
EP4665717A2 (en) * 2023-02-15 2025-12-24 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
CN120957728A (zh) * 2023-03-23 2025-11-14 海思科医药集团股份有限公司 一种二肽基肽酶小分子抑制剂的药物组合物
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (en) 2000-09-08 2002-03-14 Prozymex A/S Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
PT1325910E (pt) * 2000-10-06 2008-10-27 Mitsubishi Tanabe Pharma Corp Compostos de anel alifático de cinco membros contendo azoto
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
MXPA04005263A (es) 2001-12-04 2004-10-11 Hoffmann La Roche 2-amino-cicloalcanocarboxamidas substituidas y su uso como inhibidores de cisteina proteasa.
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
JP2006527704A (ja) * 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
EP2017620A3 (en) 2004-04-28 2009-04-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
TWI376242B (en) 2004-06-29 2012-11-11 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
AU2005274852B2 (en) 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CA2680173A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
WO2009042187A1 (en) 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
BRPI0820665A2 (pt) * 2007-12-12 2018-05-29 Astrazeneca Ab compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN105816456A (zh) 2009-04-01 2016-08-03 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
AU2010244218B2 (en) * 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
US8841463B2 (en) 2011-02-11 2014-09-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
EP2840083B1 (en) 2012-04-17 2017-09-13 Astellas Pharma Inc. Nitrogenated bicyclic aromatic heterocyclic compound
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
DK3044214T3 (da) 2013-09-09 2017-11-13 Prozymex As Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP4074312B1 (en) 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
CN107075557B (zh) 2014-05-30 2021-07-06 香港大学 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
EA032104B1 (ru) 2014-11-14 2019-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
AU2016227618B2 (en) 2015-03-05 2020-06-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
KR20250107292A (ko) 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
SI3758708T1 (sl) * 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
AU2019305565A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)- N-[(1A)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
KR20230110821A (ko) 2019-04-17 2023-07-25 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및방법
EP3980400B1 (en) 2019-06-05 2025-08-06 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4329767A4 (en) 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
KR20240099179A (ko) 2021-10-29 2024-06-28 인스메드 인코포레이티드 만성 비부비동염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
CN118695864A (zh) 2022-02-16 2024-09-24 英斯梅德股份有限公司 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺

Also Published As

Publication number Publication date
CN110483492B (zh) 2023-07-21
TWI690517B (zh) 2020-04-11
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
US9522894B2 (en) 2016-12-20
SI3097086T1 (en) 2018-04-30
CY1120049T1 (el) 2018-12-12
AU2019202675B2 (en) 2020-05-28
PL3097086T3 (pl) 2018-04-30
PH12016501439B1 (en) 2017-02-06
US20180251436A1 (en) 2018-09-06
HK1225730B (en) 2017-09-15
US20260055067A1 (en) 2026-02-26
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
JP2023156479A (ja) 2023-10-24
PL3744714T3 (pl) 2025-09-08
NZ722063A (en) 2017-09-29
IL265611A (en) 2019-05-30
PL3323814T3 (pl) 2020-10-19
NO2699580T3 (enExample) 2018-02-24
DOP2016000175A (es) 2016-08-15
US11655221B2 (en) 2023-05-23
KR20160111470A (ko) 2016-09-26
EP3323814B1 (en) 2020-05-13
JP2017503832A (ja) 2017-02-02
HRP20201147T1 (hr) 2020-12-11
US20230085620A1 (en) 2023-03-23
EP3097086B1 (en) 2017-12-13
JP2025157389A (ja) 2025-10-15
AU2015208932B8 (en) 2017-03-09
SMT201800058T1 (it) 2018-03-08
IL252836A0 (en) 2017-08-31
LT3323814T (lt) 2020-10-26
US10669245B2 (en) 2020-06-02
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
US11680049B2 (en) 2023-06-20
EA032794B1 (ru) 2019-07-31
SI3744714T1 (sl) 2025-05-30
PT3744714T (pt) 2025-04-07
US11117874B2 (en) 2021-09-14
ZA201800431B (en) 2019-09-25
RS56919B1 (sr) 2018-05-31
BR112016016224A2 (enExample) 2017-08-08
EA201691375A1 (ru) 2017-01-30
HRP20250302T1 (hr) 2025-04-25
CN110483492A (zh) 2019-11-22
RS66709B1 (sr) 2025-05-30
LT3097086T (lt) 2018-02-26
SG10201701056QA (en) 2017-03-30
US11667615B2 (en) 2023-06-06
US20230069044A1 (en) 2023-03-02
US11655222B2 (en) 2023-05-23
UY35963A (es) 2015-07-31
EP3323814A1 (en) 2018-05-23
US10287258B2 (en) 2019-05-14
AR099177A1 (es) 2016-07-06
US20200017455A1 (en) 2020-01-16
AU2018202956B2 (en) 2019-05-09
CN105980367B (zh) 2019-08-23
JP2022096662A (ja) 2022-06-29
HUE070606T2 (hu) 2025-06-28
SG11201606052TA (en) 2016-08-30
BR112016016224B1 (pt) 2023-02-23
JP6804570B2 (ja) 2020-12-23
PT3323814T (pt) 2020-08-05
PE20161218A1 (es) 2016-11-27
US20230062646A1 (en) 2023-03-02
WO2015110826A1 (en) 2015-07-30
US20230278969A1 (en) 2023-09-07
CY1123391T1 (el) 2021-12-31
JP7714823B2 (ja) 2025-07-29
DK3097086T3 (en) 2018-02-05
JP7157791B2 (ja) 2022-10-20
US20230025351A1 (en) 2023-01-26
CN105980367A (zh) 2016-09-28
AU2015208932C1 (en) 2017-05-25
MX2016009349A (es) 2016-10-13
US11673871B2 (en) 2023-06-13
US20230033573A1 (en) 2023-02-02
KR102417684B1 (ko) 2022-07-05
TW201612167A (en) 2016-04-01
US11814359B2 (en) 2023-11-14
JP6469711B2 (ja) 2019-02-13
US20230116721A1 (en) 2023-04-13
PH12016501439A1 (en) 2017-02-06
SMT202000433T1 (it) 2020-09-10
HUE052421T2 (hu) 2021-04-28
CA2935625A1 (en) 2015-07-30
ZA201605856B (en) 2020-02-26
US20200247765A1 (en) 2020-08-06
SMT202500137T1 (it) 2025-05-12
MX368840B (es) 2019-10-18
US9815805B2 (en) 2017-11-14
LT3744714T (lt) 2025-04-10
JP2019070029A (ja) 2019-05-09
CR20160327A (es) 2016-10-20
SI3323814T1 (sl) 2020-10-30
US20210238152A1 (en) 2021-08-05
CL2016001889A1 (es) 2016-12-09
CA2935625C (en) 2022-10-18
JP7336563B2 (ja) 2023-08-31
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
US11655223B2 (en) 2023-05-23
US11673872B2 (en) 2023-06-13
US20230250071A1 (en) 2023-08-10
AU2015208932A8 (en) 2017-03-09
US12054465B2 (en) 2024-08-06
US20230115170A1 (en) 2023-04-13
US20240336582A1 (en) 2024-10-10
ES2658516T3 (es) 2018-03-12
AU2019202675A1 (en) 2019-05-16
HK1255870A1 (en) 2019-08-30
RS60639B1 (sr) 2020-09-30
JP7628587B2 (ja) 2025-02-10
MY194850A (en) 2022-12-19
EP3744714B1 (en) 2025-01-15
US20170057938A1 (en) 2017-03-02
JP2025072423A (ja) 2025-05-09
ES3018635T3 (es) 2025-05-16
US20240132455A1 (en) 2024-04-25
AP2016009322A0 (en) 2016-07-31
HRP20180116T1 (hr) 2018-03-23
JP2021046423A (ja) 2021-03-25
EP3097086A1 (en) 2016-11-30
US11655224B2 (en) 2023-05-23
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (en) 2025-06-25
AU2017200338B2 (en) 2018-03-01
NZ734768A (en) 2022-09-30
US20230028726A1 (en) 2023-01-26
DK3744714T3 (da) 2025-04-07
EP4548972A2 (en) 2025-05-07
AU2015208932B2 (en) 2017-02-16
AU2018202956A1 (en) 2018-05-17
US20150210655A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
DK3744714T3 (da) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
BR112017012364A2 (pt) pré-tratamento rápido.
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3352817T3 (da) Injektionsapparat, navnlig som auto-injektor
ES1140983Y (es) Maquina de embalaje de termoconformado
LT3233862T (lt) Imidazopiridazino dariniai, kaip pi3kbeta slopikliai
DK3123576T3 (da) Modul, spesielt et industrielt modul
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
ITRM20150057U1 (it) Imballaggio per articoli.
LT3110812T (lt) Anti-amiloidų junginiai, turintys benzofurazano
UA29878S (uk) Упаковка для зубочисток
TH1601002634B (th) เครื่องติดฉลาก
UA28920S (uk) Пакет
TH1501005075A (th) สารผสมการบ่ม-ความชื้นประเภทหนึ่งห่อ
BR302014000338S1 (pt) Configuração aplicada em garrafa.
BR302014000025S1 (pt) Configuração aplicada em frasco.
ITRM20140098U1 (it) Macchina utensile.